Clinicopathological features and prognosis of pseudomyxoma peritonei

Wang,Huan; Wang,Xuejun; Ju,Yanfang; Wang,Jinliang; Zhang,Xin; Cheng,Yao; Sun,Jing; Hu,Yi

doi:10.3892/etm.2013.1408

Clinicopathological features and prognosis of pseudomyxoma peritonei

Authors:
- Huan Wang
- Xuejun Wang
- Yanfang Ju
- Jinliang Wang
- Xin Zhang
- Yao Cheng
- Jing Sun
- Yi Hu
View Affiliations

Affiliations: Department of Oncology, The General Hospital of PLA, Beijing 100853, P.R. China, Department of Neurology, Qinghai Women Children's Hospital, Xining, Qinghai 810000, P.R. China
Published online on: November 13, 2013 https://doi.org/10.3892/etm.2013.1408
Pages: 185-190

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to evaluate the effects of treatment and the factors influencing the postoperative recurrence and survival time for pseudomyxoma peritonei (PMP). A total of 39 patients with PMP who received treatment were analyzed in The General Hospital of PLA (Beijing, China) between 2002 and 2011. The patients received cytoreductive surgery (CRS) and 25 cases of PMP recurred. Seven patients received postoperative hyperthermic intraperitoneal chemoperfusion (HIPEC). The median follow‑up was 40 months. There were eight mortalities in this period. The 5‑ and 10‑year survival rates were 89.0 and 35.0%, respectively. The medians of overall survival (OS) and recurrence time were 37 and 4 months, respectively. Multivariate analyses revealed that pathological subtype was able to influence the recurrence (P=0.042) and OS (P=0.033) times, as an independent prognostic factor. HIPEC was significantly associated with postoperative recurrence time (P=0.017). Patients with disseminated peritoneal adenomucinosis had a more favorable prognosis. CRS combined with HIPEC was able to extend the postoperative recurrence time for patients with PMP.

View Figures

View References

1	Wertheim I, Fleischhacker D, McLachlin CM, Rice LW, Berkowitz RS and Goff BA: Pseudomyxoma Peritonei: a review of 23 cases. Obstet Cynecol. 84:17–21. 1994.PubMed/NCBI
2	Guo AT, Song X, Wei LX and Zhao P: Histological origin of pseudomyxoma peritonei in Chinese women: clinicopathology and immunohistochemistry. World J Gastroenterol. 17:3531–3537. 2011. View Article : Google Scholar : PubMed/NCBI
3	Sugarbaker PH: Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol. 27:239–243. 2001. View Article : Google Scholar
4	Young RH, Gilks CB and Scully RE: Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix. Am J Surg Pathol. 15:415–429. 1991. View Article : Google Scholar : PubMed/NCBI
5	Szych C, Staebler A, Connolly DC, et al: Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women. Am J Pathol. 154:1849–1855. 1999. View Article : Google Scholar : PubMed/NCBI
6	Zhou Z, Mo CC, Zhuang JY and Deng ZH: Pseudomixoma peritonei associated with ovary and omentum majus: 1 case report. Journal of Guiyang Medical College. 28:186–192. 2003.(In Chinese).
7	Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF and Coit DG: Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 241:300–308. 2005. View Article : Google Scholar : PubMed/NCBI
8	Elias D, Gilly F, Quenet F, Bereder JM, et al: Pseudomyxoma peritonei: A French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 36:456–462. 2010. View Article : Google Scholar : PubMed/NCBI
9	Smeenk RM, Verwaal VJ, Antonini N and Zoetmulder FA: Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 245:104–109. 2007. View Article : Google Scholar
10	Hsieh SY, Chiu CT, Sheen IS, Lin DY and Wu CS: A clinical study on pseudomyxoma peritonei. J Gastroenterol Hepatol. 10:86–91. 1995. View Article : Google Scholar : PubMed/NCBI
11	Carmignani CP, Hampton R, Sugarbaker CE, Chang D and Sugarbaker PH: Utility of CEA and CA19–9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol. 87:162–166. 2004.
12	Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG and Deraco M: Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 14:2300–2308. 2007. View Article : Google Scholar
13	Lee JK, Song SH, Kim I, Lee KH, Kim BG, Kim JW, Kim YT, Park SY, Cha MS and Kang SB: Retrospective multicenter study of a clinicopathologic analysis of pseudomixoma peritonei associated with ovarian tumors (KGOG 3005). Int J Gynecol Cancer. 18:916–920. 2008. View Article : Google Scholar : PubMed/NCBI
14	Miner TJ, Shia J, Jaques DP, et al: Long-term survival following treatment of pseudomixoma peritonei: an analysis of surgical therapy. Ann Surg. 241:300–308. 2005. View Article : Google Scholar : PubMed/NCBI
15	Baratti D, Kusamura S, Nonaka D, et al: Pseudomixoma Peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 15:526–534. 2008. View Article : Google Scholar
16	Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L and Sugarbaker PH: Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer. 92:85–91. 2001. View Article : Google Scholar
17	Elias D, Honoré C, Ciuchendéa R, et al: Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg. 95:1164–1171. 2008. View Article : Google Scholar
18	Sugarbaker PH: Pseudomyxoma peritonei: a cancer whose biology is characterized by a redistribution phenomenon. Ann Surg. 219:109–111. 1994. View Article : Google Scholar : PubMed/NCBI
19	Wu B and Wu HP: Dignosis and treatment of Pseudomyxoma peritonei: 5 cases report. Journal of Abdominal Surgery. 10:228–229. 1997.(In Chinese).
20	Spratt JS, Adcock RA, Sherrill W and Travathen S: Hyperthermic peritoneal perfusion system in canines. Cancer Res. 40:253–255. 1980.PubMed/NCBI
21	Zhang SH and Liu ZL: Pseudomyxoma peritonei: the treatment experience of 9 cases. Chinese Journal of Clinical Oncology. 26:1–12. 1999.(In Chinese).
22	Sugarbaker PH: Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg. 219:109–111. 1994. View Article : Google Scholar : PubMed/NCBI
23	Sugarbaker PH: Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J surg Oncol. 27:239–243. 2001. View Article : Google Scholar
24	Deraco M, Kusamura S and Gronchi A: Cytoreductive surgery (peritonectomy) and intraperitoneal hyperthermic chemotherapy: an innovative and effective approach to the treatment of pseudomyxoma peritonei. Tumori. 89:54–55. 2003.(In Italian).
25	Deraco M, Gronchi A, Mazzaferro V, et al: Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with pseudomyxoma peritonei. Tumori. 88:370–375. 2002.PubMed/NCBI
26	Gough DB, Donohue JH, Schutt AJ, et al: Pseudomyxoma peritonei. Long tern patient survival with an aggressive regional approach. Ann Surg. 219:112–119. 1994. View Article : Google Scholar : PubMed/NCBI
27	Yan TD, Black D, Savady R and Sugarbaker PH: A systematic review of the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 14:484–492. 2007. View Article : Google Scholar : PubMed/NCBI